Table 1 Patient characteristics
| Â | All cohort | Severe GVHD (grade III-IV) | Mild GVHD (grade I-II) | No GVHD | Â |
|---|---|---|---|---|---|
| Â | 51 | 9 | 18 | 24 | Â |
Male sex | 28 | 5(17.9) | 10(35.7) | 13(46.4) | Â |
Conditional regimen |  |  |  |  | P = 0.86 |
 With ATG used | 30 | 6(20) | 10(33.3) | 14(46.7) |  |
 No ATG used | 21 | 3(14.3) | 8(38.1) | 10(47.6) |  |
Age | 42(17–68) | 50(17–67) | 42(25–68) | 42(17–67) | P = 0.7 |
Diagnosis |  |  |  |  | P = 0.14 |
 Acute leukemia+MDS | 33 | 5(15.2%) | 16(48.5%) | 12(36.4%) |  |
 Chronic myeloblastic leukemia | 5 | 2(40%) | 2(40%) | 1(20%) |  |
 Lymphoma+MM |  | 1(16.7%) | 0(0%) | 5(83.3%) |  |
 Aplastic anemia+PNH |  | 1(14.3%) | 0(0%) | 6(85.7%) |  |
Donor HLA type |  |  |  |  | P = 0.49 |
 Haplo | 24 | 5(20.8%) | 10(41.7%) | 9(37.5%) |  |
 Sibling(9/10,10/10) | 22 | 4(18.2%) | 7(31.8%) | 11(50%) |  |
 MMUD | 5 | 0(0%) | 1(20%) | 4(80%) |  |
Stem cell source |  |  |  |  | P = 0.44 |
 PBSC | 27 | 4(14.8%) | 8(29.6%) | 15(55.6%) |  |
 PBSC+BM | 24 | 5(20.8%) | 10(41.7%) | 9(37.5%) |  |
Conditioning regimen |  |  |  |  | P = 0.75 |
 Myeloablative conditioning | 46 | 8(17.4%) | 17(37.0%) | 1(45.7%) |  |
 RIC | 5 | 1(0%) | 1(80%) | 3(20%) |  |